Peptide CDMO Pharmaceutical Market Growth Driven By Rising Demand For Peptide Therapeutics And Chronic Disease Management

2025-09-26 07:01:29

(MENAFN- iCrowdNewsWire)

The Peptide CDMO (Pharmaceutical) Market Size is valued at 2.5 Bn in 2024 and is predicted to reach 6.6 Bn by the year 2034 at a 10.4 % CAGR during the forecast period for 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC:

Peptide Contract Development and Manufacturing Organizations (CDMOs) specialize in the production of peptides, which are short chains of amino acids linked by peptide bonds. This process requires precise sequential assembly of amino acids according to defined sequences, often necessitating the preservation of functional groups to ensure structural and functional integrity. Peptide synthesis can be achieved through various methodologies, including solid-phase synthesis, solution-phase synthesis, and recombinant DNA technology.

The growing prevalence of chronic diseases has driven an increased demand for innovative therapeutic solutions. Peptide-based drugs offer distinct advantages, such as targeted modulation of biochemical pathways, high specificity, and the potential for lower dosing requirements. Consequently, the demand for peptide therapeutics is expanding across multiple therapeutic areas, including oncology, cardiovascular disorders, and diabetes management. CDMOs play a critical role in addressing this demand by providing specialized expertise in the development and large-scale production of peptide-based pharmaceutical products.

List of Prominent Players in the Peptide CDMO (Pharmaceutical) Market:

AmbioPharm
Auspep
Bachem
BCN Peptide
CPC Scientific
CBL- Chemical and Biopharmaceutical Laboratories
Creative Peptides
Chinese Peptide
CSBio
Corden Pharma
PolyPeptide
Hybio Pharmaceutical
Peptide Institute
Pepscan
Almac
Vivitide
CreoSalus Inc
ScinoPharm
Senn Chemicals
Wuxi AppTec
Olon
Belyntic
Ferring Pharma
Numaferm
Hybio Pharmaceutical
Provepharm Life Solutions
Enzene Biosciences
Ardena Holding
Stelis Biopharma
Piramal Pharma
Space Peptides Pharmaceutical

Expert Knowledge, Just a Click Away:

Market Dynamics:

Drivers:

The global peptide CDMO (pharmaceutical) services market is experiencing robust growth, driven by the expanding therapeutic applications of peptides, technological advancements in healthcare, and increasing interest from pharmaceutical companies in peptide-based drug development. The rising prevalence of chronic diseases and growing consumer emphasis on health and wellness further support market expansion. To enhance operational efficiency and flexibility, pharmaceutical companies are increasingly entering strategic collaborations to strengthen development, engineering, and manufacturing capabilities for peptide production. Collectively, these factors are expected to sustain significant growth in the peptide CDMO market over the forecast period.

Challenges:

Despite strong growth prospects, the market faces challenges related to the complexity and high costs of peptide manufacturing. Peptide synthesis demands specialized equipment and technical expertise, as peptides are inherently more difficult to produce than small-molecule drugs. The increasing demand for peptide therapeutics underscores the need for efficient, scalable manufacturing processes. Elevated production costs may limit access to peptide-based therapies in certain regions. Moreover, delivery mechanisms, such as cell-penetrating peptides, often transport only a fraction of the administered dose to target cells, with the remainder subject to metabolism or degradation, potentially reducing therapeutic efficacy. The COVID-19 pandemic also disrupted global supply chains, caused workforce shortages, and increased demand for diverse products, necessitating careful management of production capacity and resources.

Regional Trends:

North America is projected to capture a substantial revenue share of the global peptide CDMO market, supported by advancements in biosynthesis technologies and the growth of the chemical and pharmaceutical industries. Continued research and development, particularly in genomics and personalized therapeutics, is further driving demand for specialized CDMO services. Europe also represents a key market, underpinned by a large patient population, rising healthcare expenditures, and strong interest from multinational pharmaceutical companies seeking opportunities within the peptide CDMO sector.

Unlock Your GTM Strategy:

Recent Developments:

In March 2024, Ferring Pharmaceuticals and SK Pharmateco reached a partnership to increase the industrial production capability of Adstiladrin (nadofaragene firadenovec-vncg), the medication used in Ferring's intravesical genetic therapy.
In August 2024, AmbioPharma revealed its selection of Brian Gregg, a business veteran, as its new CEO. Mr. Gregg takes over from Tim Nieters, who is leaving the business after seven seasons and has a long history of expertise in the peptide CDMO sector.

Segmentation of Peptide CDMO (Pharmaceutical) Market-

By Scale of Operation-

Preclinical
Clinical
Commercial

By Method Used-

Chemical Synthesis Method
Non-Chemical Synthesis Method

By Applications-

Peptide Supplements
Peptide Vaccines
Peptides as Radio-theranostic Agents
Cell-penetrating Peptides (CPPs)
Affinity Ligands
Protein Mimics

By Synthesis Types-

LPPS
SPPS
Mixed Phase

By Region-

North America-

The US
Canada
Mexico

Europe-

Germany
The UK
France
Italy
Spain
Rest of Europe

Asia-Pacific-

China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific

Latin America-

Brazil
Argentina
Rest of Latin America

Middle East & Africa-

GCC Countries
South Africa
Rest of the Middle East and Africa

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Tags: Peptide CDMO (Pharmaceutical) Market See Campaign:
Contact Information:

Tags:
CE , Extended Distribution , Go Media , Go Media2 , iCN Internal Distribution , Reportedtimes , Research Newswire , English

MENAFN26092025003318003403ID1110117194

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.